Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36300887)

  • 1. Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.
    Hou Y; Zi J; Liu S; Ge Q; Ge Z
    Mol Carcinog; 2023 Feb; 62(2):200-209. PubMed ID: 36300887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
    Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
    Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
    Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
    Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
    Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
    Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
    Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
    Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of gene mutation profiles by next-generation sequencing in diffuse large B-cell lymphoma.
    Özçalımlı A; Erdoğdu İH; Turgutkaya A; Yavaşoğlu İ; Döger FK; Bolaman AZ
    Int J Lab Hematol; 2023 Jun; 45(3):310-316. PubMed ID: 36576110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes.
    Kim JJ; Kim HM; Kim H; Kim SJ; Lee ST; Choi JR; Shin S; Hwang DY
    Cancer Res Treat; 2024 Jan; 56(1):314-323. PubMed ID: 37475138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mutational Spectrum and Prognosis Analysis of Young Patients with Diffuse Large B-Cell Lymphoma Based on Next-Generation Sequencing].
    Lyu LY; Nie YL; Renaguli A; Qi XL; Muhebaier A; Zhai SS; An L; Mao M; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):403-410. PubMed ID: 37096512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.
    Zhao K; Zheng X; Liu X; Liu T; Ke Z; Zhu F; Wen Q; Xin B; Li Q; Zhang L
    Oncologist; 2024 May; 29(5):e672-e680. PubMed ID: 38297976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA in Lymphoma.
    Kambhampati S; Zain J
    Curr Hematol Malig Rep; 2022 Dec; 17(6):298-305. PubMed ID: 36214943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.
    Grønbaek K; Worm J; Ralfkiaer E; Ahrenkiel V; Hokland P; Guldberg P
    Blood; 2002 Aug; 100(4):1430-7. PubMed ID: 12149228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.
    Rivas-Delgado A; Nadeu F; Enjuanes A; Casanueva-Eliceiry S; Mozas P; Magnano L; Castrejón de Anta N; Rovira J; Dlouhy I; Martín S; Osuna M; Rodríguez S; Simó M; Pinyol M; Baumann T; Beà S; Balagué O; Delgado J; Villamor N; Setoain X; Campo E; Giné E; López-Guillermo A
    Clin Cancer Res; 2021 Jan; 27(2):513-521. PubMed ID: 33122345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma.
    Bastos-Oreiro M; Suárez-González J; Andrés-Zayas C; Carrión NC; Moreno S; Carbonell D; Chicano M; Muñiz P; Sanz L; Diaz-Crespo FJ; Menarguez J; Diez-Martín JL; Buño I; Martínez-Laperche C
    Sci Rep; 2021 Nov; 11(1):22815. PubMed ID: 34819573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.
    Li M; Ding N; Mi L; Shi Y; Du X; Yi Y; Yang L; Liu W; Zhu J
    Leuk Lymphoma; 2022 Mar; 63(3):608-617. PubMed ID: 34751093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses.
    Todorovic Balint M; Jelicic J; Mihaljevic B; Kostic J; Stanic B; Balint B; Pejanovic N; Lucic B; Tosic N; Marjanovic I; Stojiljkovic M; Karan-Djurasevic T; Perisic O; Rakocevic G; Popovic M; Raicevic S; Bila J; Antic D; Andjelic B; Pavlovic S
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27164089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.